Johnson & Johnson (JNJ) stock
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3085% above fair value
$270.47+3.33 (+1.25%)
Close on Nov 20, 2026Market cap $651.11BP/E 41.0Yield 1.90%
Johnson & Johnson net income
Net income is the profit left for shareholders after every expense, interest and tax.
Johnson & Johnson's net income for the twelve months ending Sep 27, 2026 was $16.10B, down 35.9% year over year. For fiscal 2025 it was $26.80B, up 90.6% from the year before. Over ten years it grew 5.7% a year on average. The highest annual figure on record is $35.15B in fiscal 2023.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $26.80B | +90.6% |
| FY2024 | Dec 29, 2024 | $14.07B | -60.0% |
| FY2023 | Dec 31, 2023 | $35.15B | +95.9% |
| FY2022 | Jan 1, 2023 | $17.94B | -14.1% |
| FY2021 | Jan 2, 2022 | $20.88B | +41.9% |
| FY2020 | Jan 3, 2021 | $14.71B | -2.7% |
| FY2019 | Dec 29, 2019 | $15.12B | -1.2% |
| FY2018 | Dec 30, 2018 | $15.30B | +1076.7% |
| FY2017 | Dec 31, 2017 | $1.30B | -92.1% |
| FY2016 | Jan 1, 2017 | $16.54B | +7.3% |
| FY2015 | Jan 3, 2016 | $15.41B | -5.6% |
| FY2014 | Dec 28, 2014 | $16.32B | +18.0% |
| FY2013 | Dec 29, 2013 | $13.83B | +27.4% |
| FY2012 | Dec 30, 2012 | $10.85B | +12.2% |
| FY2011 | Jan 1, 2012 | $9.67B | -27.5% |
| FY2010 | Jan 2, 2011 | $13.33B | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $210.00M | -95.9% |
| Q2 FY2026 | Jun 28, 2026 | $5.53B | -0.1% |
| Q1 FY2026 | Mar 29, 2026 | $5.24B | -52.4% |
| Q4 FY2025 | Dec 28, 2025 | $5.12B | +49.1% |
| Q3 FY2025 | Sep 28, 2025 | $5.15B | +91.2% |
| Q2 FY2025 | Jun 29, 2025 | $5.54B | +18.2% |
| Q1 FY2025 | Mar 30, 2025 | $11.00B | +237.9% |
| Q4 FY2024 | Dec 29, 2024 | $3.43B | -15.3% |
| Q3 FY2024 | Sep 29, 2024 | $2.69B | -89.6% |
| Q2 FY2024 | Jun 30, 2024 | $4.69B | -8.9% |
| Q1 FY2024 | Mar 31, 2024 | $3.26B | – |
| Q4 FY2023 | Dec 31, 2023 | $4.05B | +15.0% |
| Q3 FY2023 | Oct 1, 2023 | $26.03B | +483.8% |
| Q2 FY2023 | Jul 2, 2023 | $5.14B | +6.9% |
| Q1 FY2023 | Apr 2, 2023 | -$68.00M | -101.3% |
| Q4 FY2022 | Jan 1, 2023 | $3.52B | -25.7% |
| Q3 FY2022 | Oct 2, 2022 | $4.46B | +21.6% |
| Q2 FY2022 | Jul 3, 2022 | $4.81B | -23.3% |
| Q1 FY2022 | Apr 3, 2022 | $5.15B | -16.9% |
| Q4 FY2021 | Jan 2, 2022 | $4.74B | +172.5% |
| Q3 FY2021 | Oct 3, 2021 | $3.67B | +3.2% |
| Q2 FY2021 | Jul 4, 2021 | $6.28B | +73.1% |
| Q1 FY2021 | Apr 4, 2021 | $6.20B | +6.9% |
| Q4 FY2020 | Jan 3, 2021 | $1.74B | -56.7% |
| Q3 FY2020 | Sep 27, 2020 | $3.55B | +102.7% |
| Q2 FY2020 | Jun 28, 2020 | $3.63B | -35.3% |
| Q1 FY2020 | Mar 29, 2020 | $5.80B | +54.6% |
| Q4 FY2019 | Dec 29, 2019 | $4.01B | +31.8% |
| Q3 FY2019 | Sep 29, 2019 | $1.75B | -55.4% |
| Q2 FY2019 | Jun 30, 2019 | $5.61B | +41.8% |
| Q1 FY2019 | Mar 31, 2019 | $3.75B | -14.2% |
| Q4 FY2018 | Dec 30, 2018 | $3.04B | – |
| Q3 FY2018 | Sep 30, 2018 | $3.93B | +4.5% |
| Q2 FY2018 | Jul 1, 2018 | $3.95B | +3.3% |
| Q1 FY2018 | Apr 1, 2018 | $4.37B | -1.2% |
| Q4 FY2017 | Dec 31, 2017 | -$10.71B | -380.9% |
| Q3 FY2017 | Oct 1, 2017 | $3.76B | – |
| Q2 FY2017 | Jul 2, 2017 | $3.83B | – |
| Q1 FY2017 | Apr 2, 2017 | $4.42B | – |
| Q4 FY2016 | Jan 1, 2017 | $3.81B | – |
See a number that looks wrong?